Enadenotucirev
Enadenotucirev is an investigational oncolytic virus that is entering clinical trials for various cancers.[1]
It is an oncolytic A11/Ad3 Chimeric Group B Adenovirus, previously described as oncolytic vaccine ColoAd1.[2]
It is intended to be modified with additional genes to treat different conditions.[1]
In Jan 2015 the European Medicines Agency's (EMA) Committee for Orphan Medical Products (COMP) gave a positive review of enadenotucirev to treat platinum-resistant ovarian cancer.[3]
Clinical trials
As of December 2015[update] Two phase 1 trials have been registered:[4] EVOLVE[5] and OCTAVE (in ovarian cancer).[6]
In 2014, positive results from EVOLVE were reported.[2]
OCTAVE started phase 1b in March 2016[7] and is due to complete around March 2017.[6]
The Study of Pembrolizumab In Combination with Enadenotucirev (SPICE) study (not yet on clinicaltrials.gov) will assess if enadenotucirev can reverse resistance to checkpoint inhibitors for various tumour types, including metastatic colorectal cancer.[1]
See also
References
- ^ a b c PsiOxus Therapeutics Initiates Combination Study of Merck’s Keytruda with Oncolytic Virus Enadenotucirev. Dec 2015
- ^ a b PsiOxus Therapeutics announces positive study results of oncolytic vaccine enadenotucirev at 2014 ASCO annual meeting
- ^ Ovarian cancer oncolytic vaccine receives positive reviews. an 2015
- ^ Enadenotucirev trials
- ^ Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients (EVOLVE)
- ^ a b Phase I / II Study Of Enadenotucirev Intraperitoneally in Ovarian Cancer Patients (OCTAVE)
- ^ PsiOxus Therapeutics Initiates Combination of Paclitaxel with Oncolytic Virus Enadenotucirev in Ovarian Cancer Study
 | This oncology article is a stub. You can help Wikipedia by expanding it. |